Research programme: gene therapeutics - Libella Gene Therapeutics

Drug Profile

Research programme: gene therapeutics - Libella Gene Therapeutics

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Libella Gene Therapeutics
  • Class Antidementias; Gene therapies
  • Mechanism of Action Gene transference; Telomerase activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 13 Dec 2017 Gene therapeutics - Libella Gene Therapeutics is available for licensing in USA as of 13 Dec 2017. http://www.libellagenetherapeutics.com/mission/
  • 06 Dec 2017 Libella Gene Therapeutics plans a clinical trial for Alzheimer's disease in Colombia in first quarter of 2018
  • 06 Dec 2017 Libella Gene Therapeutics in-licenses technology from Sierra Sciences for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top